Ophthotech Product Pipeline
FovistaTM Anti-PDGF Therapy
FovistaTM, previously known as E10030, is designed to target platelet derived growth factor (PDGF) in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. In clinical trials, the combination of FovistaTM 1.5mg and an anti-VEGF therapy demonstrated statistically significant superiority compared to anti-VEGF monotherapy in terms of improvements in visual acuity, providing a 62% comparative benefit from baseline.
FovistaTM binds to and inhibits PDGF expression, causing the loss or stripping of pericytes, leaving the endothelial cells unprotected and highly vulnerable to the effects of anti-VEGF therapy. Clinical data have shown that administration of FovistaTM 1.5mg in combination with anti-VEGF drugs is likely to inhibit new blood vessel growth in patients with wet AMD more effectively than anti-VEGF monotherapy and may also enhance neovascular regression.
ARC1905 – Anti-Complement
ARC1905 targets complement factor C5, a central component of the complement cascade that is believed to be involved in the development of AMD. In a phase 1/2a clinical trial of ARC1905, wet AMD patients who had not previously been treated with anti-VEGF therapy and who received six injections of ARC1905 in combination with anti-VEGF treatment showed improvements in vision of a magnitude warranting further evaluation in subsequent studies.
Ophthotech is evaluating a study of ARC1905 in combination with anti-VEGF therapies in patients with wet AMD who do not respond adequately to treatment with anti-VEGF monotherapy on the basis of complement mediation inflammation.
Both FovistaTM and ARC1905 are aptamers, single strands of nucleic acid that bind with high specificity and affinity to targets such as PDGF, similar to a monoclonal antibody. Aptamers are synthetically derived, making their production predictable and reproducible. They are also chemically stable and do not generate an immune response that could limit efficacy.